ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Opioid Analgesic (Partial Agonist) Pregnancy: Use with caution — neonatal opioid withdrawal syndrome risk; NICE guidance: buprenorphine preferred over methadone for pregnant women requiring opioid substitution in some cases

Buprenorphine (Surgical — Analgesia)

Brand names: Temgesic (sublingual), BuTrans (patch), Norspan (patch)

Adult dose

Dose: Sublingual: 200–400 mcg every 6–8 hours; Patch: BuTrans 5–20 mcg/hour (7-day patch); IV (specialist): 300–600 mcg IM/slow IV
Route: Sublingual / Transdermal / IM or IV
Frequency: Every 6–8 hours (SL); once weekly (patch)
Max: 1.8 mg/day (sublingual); 40 mcg/hour patch
Partial mu-opioid agonist with ceiling effect on respiratory depression — safer margin than full agonists. High receptor affinity — can precipitate withdrawal if given to opioid-dependent patients. Patch useful for chronic post-surgical pain. Minimally excreted via kidneys — preferred opioid in renal failure.

Paediatric dose

Dose: 2–6 mcg/kg
Route: IM or IV
Frequency: Every 6–8 hours
Max: 6 mcg/kg per dose
Not routinely recommended under 6 years. Children 6–12 years: 3 mcg/kg IM/slow IV. Use only under specialist anaesthetic guidance.

Dose adjustments

Renal

Preferred opioid in renal failure — no active metabolite accumulation. No dose adjustment needed for mild-moderate renal impairment.

Hepatic

Caution in severe hepatic impairment — increased buprenorphine levels; reduce dose and increase monitoring.

Paediatric weight-based calculator

Not routinely recommended under 6 years. Children 6–12 years: 3 mcg/kg IM/slow IV. Use only under specialist anaesthetic guidance.

Clinical pearls

  • Opioid-sparing multimodal analgesia: buprenorphine patch BuTrans 5 mcg/hour can be initiated pre-operatively for patients requiring opioid analgesia post-major surgery who have renal failure — avoids morphine and codeine metabolite accumulation
  • MHRA 2016 warning: fatal respiratory depression reported with buprenorphine + benzodiazepine combination in opioid substitution therapy — the same pharmacodynamic risk applies in perioperative settings; reduce both drugs if combined
  • Partial agonist ceiling: buprenorphine has a 'ceiling' on respiratory depression but NOT on analgesia — useful safety feature perioperatively, but in opioid-tolerant patients may provide less analgesia than full agonists (morphine/oxycodone) at equianalgesic doses

Contraindications

  • Acute alcohol intoxication
  • Concurrent naltrexone (blocks opioid effects — precipitates withdrawal)
  • Severe respiratory depression
  • Raised intracranial pressure (relative — in surgical context)

Side effects

  • Nausea and vomiting
  • Dizziness
  • Constipation (less than full agonists)
  • Ceiling on respiratory depression (partial agonism — plateau effect)
  • Contact dermatitis (transdermal patch)
  • Precipitates withdrawal in opioid-dependent patients

Interactions

  • Benzodiazepines and CNS depressants (MHRA 2016 black box warning: increased risk of respiratory depression and death — opioid + benzo combination; avoid or minimise dose)
  • MAOIs (avoid — serotonergic crisis risk; buprenorphine has partial serotonergic activity)
  • CYP3A4 inhibitors (azoles, macrolides — increase buprenorphine levels)

Monitoring

  • Respiratory rate and SpO2
  • Pain scores
  • Sedation score (RAMSAY or CPOT in ICU)
  • Withdrawal signs if abruptly stopped in dependent patients

Reference: BNFc; BNF 90; MHRA Drug Safety Update 2016 (opioid + benzo); NICE NG215 (Chronic Pain); BNFc; NICE NG193 (Acute Pain in Adults). Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways